The Beckley / Imperial Research Programme aims to develop a comprehensive account of how substances such as LSD, psilocybin, DMT and MDMA affect the brain to alter consciousness, and how they produce their potentially therapeutic effects. We use the latest developments in brain imaging technology and analysis methods to measure brain blood flow, brain network connectivity, and neural oscillations (rhythmical activity, or ‘brain waves’) during the psychedelic experience. This understanding greatly adds to the evidence base supporting the therapeutic potential of these substances, while teaching us about consciousness itself. Our studies have resulted in over 20 publications in high-impact scientific journals.
David Nutt, together with Amanda Feilding, is Co-Director of the Programme. Prof. Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.
Robin Carhart-Harris is the lead investigator of the Beckley / Imperial Research Programme. He has a degree in Psychology, MA in Psychoanalysis, and PhD in the field of Psychopharmacology, and is currently a Research Associate in the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.
Mendel Kaelen was a Beckley / Imperial Research Programme Fellow, and a PhD student in the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London and also a musician. His dissertation project investigates the interaction between LSD and music.
Other Beckley / Imperial research collaborators include Leor Roseman, Chris Timmerman, and Tobias Buchborn.
This collaboration was formed in 2005, when Amanda convinced David Nutt – then at the University of Bristol – that they should form a collaborative partnership. She also suggested that Robin Carhart-Harris carry out his PhD under Nutt’s supervision. In 2009, David Nutt moved to Imperial College London, and their collaboration became the Beckley / Imperial Research Programme, with Amanda and David as co-directors and Robin as lead investigator. In 2012, the first results of their brain imaging study with psilocybin were published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS) and achieved world-wide publicity. Based on this work, the Programme later received a substantial grant from the Medical Research Council to study the effects of psilocybin in the treatment of depression.
Also in 2012, the Beckley / Imperial Research Programme carried out the first brain imaging study of MDMA (‘Ecstasy’), as part of the Channel 4 programme Drugs Live: The Ecstasy Trial. This was the first detailed study to map the neural underpinnings of MDMA’s effects, and to explain why it is so valuable for psychotherapy.
In 2014, the Programme, at last, launched the first-ever brain imaging study with LSD – a study Amanda has longed to do ever since the 1960s. The results have proven to be as ground-breaking as those of the psilocybin studies. To supplement the funding to complete the study, the Beckley Foundation launched a successful crowdfunding campaign with the website Walacea.
Future Beckley / Imperial studies will continue to investigate the effects of psychedelics, MDMA, and cannabinoids, their neurobiological mechanisms, and the potential therapeutic benefit they may have in a variety of conditions.
Media coverage of the Beckley/Imperial research on LSD
Media coverage of the Beckley/Imperial research on MDMA: Imperial college press release, the Guardian, BBC news, and watch researchers Dr Robin Carhart-Harris and Dr David Erritzoe discussing this study
2017, Scientific Reports
Psychopharmacology , 2017
Scientific Reports, 2017
Language, Cognition and Neuroscience, 2016
Lancet Psychiatry, 2016
Psychological Medicine, 2016
Human Brain Mapping, 2016
Journal of Psychopharmacology, 2016
Human Brain Mapping, 2016
Proceedings of the National Academy of Sciences of the USA, 2016
Current Biology, 2016
European Neuropsychopharmacology, 2016
Biological Psychiatry, 2014
Human Brain Mapping, 2015
Human brain mapping, 2014
Frontiers in human neuroscience, 2014
International Journal of Neuropsychopharmacology, 2014
Current Drug Abuse Reviews, 2014
Journal of The Royal Society Interface, 2014
Frontiers in Human Neuroscience, 2014
Schizophrenia bulletin, 2013
The Journal of Neuroscience, 2013
The British Journal of Psychiatry, 2012
Proceedings of the National Academy of Sciences of the USA, 2012
Journal of Psychopharmacology, 2010
Psilocybin for Depression
Type of publication